Europe Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2030

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 DBMR TRIPOD DATA VALIDATION MODEL 35
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.6 MULTIVARIATE MODELLING 39
2.7 MARKET END USER COVERAGE GRID 40
2.8 PROCESS LIFELINE CURVE 41
2.9 DBMR MARKET POSITION GRID 42
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 PESTEL ANALYSIS 51
4.2 POTERS FIVE FORCES 52
5 EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 53
6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 59
6.1.2 RISE IN CHRONIC DISEASES 59
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 60
6.1.4 GROWTH IN BIOLOGICS 61
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 61

6.2 RESTRAINTS 62
6.2.1 RISE IN COST OF FORMULATED DRUG 62
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.3 OPPORTUNITIES 63
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 63
6.3.2 RISE IN HEALTHCARE EXPENDITURE 63
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 64
6.4 CHALLENGES 64
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 64
6.4.2 STRINGENT REGULATIONS 65
7 IMPACT OF COVID-19 ON EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 66
7.1 IMPACT ON PRICE 66
7.2 IMPACT ON DEMAND 66
7.3 IMPACT ON SUPPLY CHAIN 67
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 67
7.5 CONCLUSION 68
8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 69
8.1 OVERVIEW 70
8.2 TARGET SELECTION 73
8.3 TARGET VALIDATION 73
8.4 HIT-TO-LEAD IDENTIFICATION 74
8.5 LEAD OPTIMIZATION 75
8.6 CANDIDATE VALIDATION 76
9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 77
9.1 OVERVIEW 78
9.2 FRAGMENT-BASED VARIATION 81
9.3 STRUCTURE BASED DRUG DESIGN 81
9.4 DIVERSITY ORIENTED SYNTHESIS 82
9.5 CHEMOGENOMICS 83
9.6 NATURAL PRODUCTS 84
9.7 OTHERS 85
10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 86
10.1 OVERVIEW 87
10.2 SMALL MOLECULES 90
10.3 BIOLOGICS 91
11 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 92
11.1 OVERVIEW 93
11.2 ONCOLOGY 96
11.3 NEUROLOGY 96
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 97
11.5 CARDIOVASCULAR DISEASES 98
11.6 DIGESTIVE SYSTEM DISEASES 99
11.7 OTHERS 100
12 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 101
12.1 OVERVIEW 102
12.2 CONTRACT RESEARCH ORGANIZATION 106
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 106
12.4 ACADEMIC AND RESEARCH INSTITUTES 107
12.5 OTHERS 108
13 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY REGION 109
13.1 EUROPE 110
13.1.1 GERMANY 116
13.1.2 FRANCE 118
13.1.3 U.K. 120
13.1.4 ITALY 122
13.1.5 SPAIN 124
13.1.6 NETHERLANDS 126
13.1.7 RUSSIA 128
13.1.8 SWITZERLAND 130
13.1.9 BELGIUM 132
13.1.10 TURKEY 134
13.1.11 AUSTRIA 136
13.1.12 NORWAY 138
13.1.13 HUNGARY 140
13.1.14 LITHUANIA 142
13.1.15 IRELAND 144
13.1.16 POLAND 146
13.1.17 REST OF EUROPE 148

14 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 149
14.1 COMPANY SHARE ANALYSIS: EUROPE 149
15 SWOT ANALYSIS 150
16 COMPANY PROFILE 151
16.1 EUROFINS SCIENTIFIC 151
16.1.1 COMPANY SNAPSHOT 151
16.1.2 REVENUE ANALYSIS 152
16.1.3 COMPANY SHARE ANALYSIS 152
16.1.4 SERVICE PORTFOLIO 152
16.1.5 RECENT DEVELOPMENT 153
16.2 LABCORP DRUG DEVELOPMENT 154
16.2.1 COMPANY SNAPSHOT 154
16.2.2 REVENUE ANALYSIS 155
16.2.3 COMPANY SHARE ANALYSIS 155
16.2.4 SERVICE PORTFOLIO 156
16.2.5 RECENT DEVELOPMENT 156
16.3 CHARLES RIVER 157
16.3.1 COMPANY SNAPSHOT 157
16.3.2 REVENUE ANALYSIS 157
16.3.3 COMPANY SHARE ANALYSIS 158
16.3.4 SERVICE PORTFOLIO 158
16.3.5 RECENT DEVELOPMENTS 158
16.4 WUXI APPTEC 159
16.4.1 COMPANY SNAPSHOT 159
16.4.2 REVENUE ANALYSIS 159
16.4.3 COMPANY SHARE ANALYSIS 160
16.4.4 SERVICE PORTFOLIO 160
16.4.5 RECENT DEVELOPMENTS 160
16.5 EVOTEC SE 161
16.5.1 COMPANY SNAPSHOT 161
16.5.2 REVENUE ANALYSIS 161
16.5.3 COMPANY SHARE ANALYSIS 162
16.5.4 SERVICE PORTFOLIO 162
16.5.5 RECENT DEVELOPMENTS 162

16.6 PIRAMAL PHARMA SOLUTIONS 163
16.6.1 COMPANY SNAPSHOT 163
16.6.2 SERVICE PORTFOLIO 163
16.6.3 RECENT DEVELOPMENTS 163
16.7 THERMO FISHER SCIENTIFIC INC. 164
16.7.1 COMPANY SNAPSHOT 164
16.7.2 REVENUE ANALYSIS 164
16.7.3 SERVICE PORTFOLIO 165
16.7.4 RECENT DEVELOPMENT 165
16.7.4.1 ACQUISITION 165
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 166
16.8.1 COMPANY SNAPSHOT 166
16.8.2 REVENUE ANALYSIS 166
16.8.3 SERVICE PORTFOLIO 167
16.8.4 RECENT DEVELOPMENT 167
16.9 AURELIA BIOSCIENCES 168
16.9.1 COMPANY SNAPSHOT 168
16.9.2 SERVICE PORTFOLIO 168
16.9.3 RECENT DEVELOPMENTS 168
16.10 BIOBLOCKS INC 169
16.10.1 COMPANY SNAPSHOT 169
16.10.2 SERVICE PORTFOLIO 169
16.10.3 RECENT DEVELOPMENT 169
16.11 CERTARA INC 170
16.11.1 COMPANY SNAPSHOT 170
16.11.2 REVENUE ANALYSIS 170
16.11.3 SERVICE PORTFOLIO 171
16.11.4 RECENT DEVELOPMENTS 171
16.12 DOMAINEX 172
16.12.1 COMPANY SNAPSHOT 172
16.12.2 SERVICE PORTFOLIO 172
16.12.3 RECENT DEVELOPMENT 172
16.13 DRUG DISCOVERY ALLIANCES 173
16.13.1 COMPANY SNAPSHOT 173
16.13.2 SERVICE PORTFOLIO 173
16.13.3 RECENT DEVELOPMENT 173
16.14 GENSCRIPT BIOTECH 174
16.14.1 COMPANY SNAPSHOT 174
16.14.2 REVENUE ANALYSIS 174
16.14.3 SERVICE PORTFOLIO 175
16.14.4 RECENT DEVELOPMENT 175
16.15 JUBILANT BIOSYS 176
16.15.1 COMPANY SNAPSHOT 176
16.15.2 SERVICE PORTFOLIO 176
16.15.3 RECENT DEVELOPMENTS 176
16.16 NANOSYN 178
16.16.1 COMPANY SNAPSHOT 178
16.16.2 PRODUCT PORTFOLIO 178
16.16.3 RECENT DEVELOPMENT 178
16.17 NEREID THERAPEUTICS 179
16.17.1 COMPANY SNAPSHOT 179
16.17.2 SERVICE PORTFOLIO 179
16.17.3 RECENT DEVELOPMENT 179
16.18 PFIZER INC. 180
16.18.1 COMPANY SNAPSHOT 180
16.18.2 REVENUE ANALYSIS 180
16.18.3 SERVICE PORTFOLIO 181
16.18.4 RECENT DEVELOPMENTS 181
16.19 SELVITA 182
16.19.1 COMPANY SNAPSHOT 182
16.19.2 REVENUE ANALYSIS 182
16.19.3 SERVICE PORTFOLIO 183
16.19.4 RECENT DEVELOPMENTS 183
16.19.4.1 ACQUISITION 183
16.20 SPECTRIS PLC 184
16.20.1 COMPANY SNAPSHOT 184
16.20.2 REVENUE ANALYSIS 184
16.20.3 SERVICE PORTFOLIO 185
16.20.4 RECENT DEVELOPMENT 185
16.21 SYGNATURE DISCOVERY 186
16.21.1 COMPANY SNAPSHOT 186
16.21.2 SERVICE PORTFOLIO 186
16.21.3 RECENT DEVELOPMENTS 186
16.22 TAROS CHEMICAL GMBH 187
16.22.1 COMPANY SNAPSHOT 187
16.22.2 SERVICE PORTFOLIO 187
16.22.3 RECENT DEVELOPMENT 187
17 QUESTIONNAIRE 188
18 RELATED REPORTS 191